美国FDA于2016年1月28日批准一种化疗药Halaven(eribulin mesylate,甲磺酸艾瑞布林),治疗脂肪肉瘤(STS,软组织肉瘤特定类型),无法通过手术(切除)或者晚期(转移性)瘤。这种治疗被批准在先前接受过蒽环类药物的化疗患者。Halaven是首个治疗脂肪肉瘤批准的药物,并证明对生存时间有改善。(源自:药品资讯网) The FDA approved a chemotherapeutic drug, Halaven (eribulin mesylate) on January 28, 2016 for the treatment of liposarcoma (STS, a specific type of soft tissue sarcoma) that can not be surgically (resected) or advanced Sexual) tumor. This treatment is approved for patients who have previously received anthracycline chemotherapy. Halaven is the first drug approved for the treatment of liposarcoma and has demonstrated an improvement in survival. (From: Drug Information Network)